Q3 2024 delivered flat sales with 1% organic growth, strong cash flow, and margin resilience despite currency headwinds and higher M&A costs. Medical and Asian segments outperformed, while machinery and construction softened, prompting a slight downward revision to full-year guidance.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.